219862-14-3

Basic information

• Product Name: BOC-3-AMINO-1,2,3,4-TETRAHYDROQUINOLINE
• Synonyms: BOC-3-AMINO-1,2,3,4-TETRAHYDROQUINOLINE;(1,2,3,4-Tetrahydro-quinolin-3-yl)-carbamic acid tert-butyl ester;tert-Butyl (1,2,3,4-tetrahydroquinolin-3-yl)
• CAS NO: 219862-14-3
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.32
• Product Categories: pharmacetical
• Mol File: 219862-14-3.mol

Chemical Properties

• Boiling Point: 406.8°Cat760mmHg
• Flash Point: 199.8°C
• Appearance: /
• Density: 1.11g/cm³
• Vapor Pressure: 7.9E-07mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.04±0.20(Predicted)
• CAS DataBase Reference: BOC-3-AMINO-1,2,3,4-TETRAHYDROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-3-AMINO-1,2,3,4-TETRAHYDROQUINOLINE(219862-14-3)
• EPA Substance Registry System: BOC-3-AMINO-1,2,3,4-TETRAHYDROQUINOLINE(219862-14-3)

Safety Data

• Hazardous Substances Data: 219862-14-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BOC-3-AMINO-1,2,3,4-TETRAHYDROQUINOLINE is used as a building block in organic synthesis for the creation of complex molecules and drug candidates. Its versatility and ability to be modified for various chemical reactions make it an essential component in the development of new pharmaceuticals.
Used in Drug Synthesis:
BOC-3-AMINO-1,2,3,4-TETRAHYDROQUINOLINE is used as a key intermediate in the synthesis of various drugs, particularly those targeting complex molecular structures. Its presence in the synthesis process aids in the formation of the desired pharmaceutical compounds.
Used in Drug Discovery:
BOC-3-AMINO-1,2,3,4-TETRAHYDROQUINOLINE is used as a research tool in drug discovery, where its potential biological activities are explored, including its potential as an antitumor agent. This application helps in identifying new therapeutic agents for the treatment of various diseases.
Used in Chemical Research:
BOC-3-AMINO-1,2,3,4-TETRAHYDROQUINOLINE is used as a subject of study in chemical research to understand its reactivity, stability, and potential applications in various chemical processes. This research contributes to the advancement of organic chemistry and the development of new synthetic methods.

InChI:InChI=1/C14H20N2O2/c1-14(2,3)18-13(17)16-11-8-10-6-4-5-7-12(10)15-9-11/h4-7,11,15H,8-9H2,1-3H3,(H,16,17)

Upstream product

• 580-17-6 3-aminoquinoline 
• 890839-20-0 tert-butyl 1-benzyl-1,2,3,4-tetrahydroquinolin-3-ylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 219862-13-2 3-(tert-butoxycarbonyl)aminoquinoline 

Downstream Products

• 219862-37-0 N-(6-Cyano-1,2,3,4-tetrahydro-3-quinolinyl)benzene-sulfonamide 
• 851758-74-2 N-(6-cyano-1,2,3,4-tetrahydro-quinolin-3-yl)-benzenesulfonamide 
• 851758-75-3 N-(6-cyano-1,2,3,4-tetrahydro-quinolin-3-yl)-benzenesulfonamide 
• 851758-69-5 N-[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-benzenesulfonamide 
• 851759-03-0 N-[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-benzenesulfonamide 
• 851759-02-9 N-[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-benzenesulfonamide 
• 890840-32-1 C₂₂H₂₅F₃N₂O₂ 
• 890839-20-0 tert-butyl 1-benzyl-1,2,3,4-tetrahydroquinolin-3-ylcarbamate 
• 1266103-77-8 C₂₀H₂₂Cl₂N₂O₂ 
• 1364165-30-9 3-(3-Methoxy-benzoylamino)-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid hydroxyamide 

Relevant articles and documents

NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to proc

NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to proc

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

Bicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, n, and Z are described herein.

Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion as

Inhibitors of farnesyl protein transferase

Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.